Abide Therapeutics

Our mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in nature with validated, but mostly untapped therapeutic potential. Hundreds of serine hydrolases exist in humans and include lipases, amidases, esterases, thioesterases, proteases and peptidases, which all share a base-activated serine nucleophile that cleaves an amide or ester bond. Serine hydrolases play a key role in regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, life cycle of viruses and pathogens. The Abide technology selectively and near-universally targets this enzyme class in their native configuration for functional profiling and inhibitor discovery and optimization.